Upstream Bio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-2.2%projected annual EPS growth
Analyst Coverage
8analysts covering
FY EPS (est.)
-$2.90next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Short-Term Investments Quarterly294.6MTarget: Sufficient to fund planned operations through 2027
Research and Development (R&D) Expenses Quarterly36.6MTarget: Reflective of clinical trial progression and manufacturing scale-up
General and Administrative (G&A) Expenses Quarterly8.1MTarget: Reflective of public company operations and personnel-related costs
Watch Items
- End-of-Phase 2 FDA Meetings for VerekitugTrigger: FDA feedback on Phase 3 trial designs for severe asthma and CRSwNPAction: Finalize Phase 3 protocols and prepare for trial initiations
- Phase 3 Trial Initiations for Severe Asthma and CRSwNPTrigger: First patient dosed in Phase 3 trialsAction: Initiate dosing in Q1 2027 as planned
- Phase 2 VENTURE Trial in COPDTrigger: Capping of enrollment and subsequent data readoutAction: Monitor trial progress toward expected data readout in H2 2027
Research as of 20 Jun 2026